Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:


9/29/2014 Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators … Hemispherx’s Two Experimental Therapeutics May Provide Benefit Despite Recently Discovered Ebola Viral Mutations

9/22/2014 Hemispherx Announces Primate Research Showing Alferon® LDO Protection from Pulmonary Damage Associated with Infection by Highly Pathogenic Influenza Virus
….WHO Reports Global Flu Reaches 5 Year High in Southern Hemisphere

9/15/2014 Hemispherx’ Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
…… Antibodies Against Flu Strains with Pandemic Potential Observed

9/10/2014 Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon® and Ampligen® Against the Ebola Virus
… WHO declares “a clinical emergency all over the world.”

9/8/2014 Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon® and Ampligen® Against the Ebola Virus
Ebola Studies to be conducted at USAMRIID’s Laboratories at Ft. Detrick, Maryland

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP


Investor Relations:

Charles Jones
CJones & Associates Public Relations